Intermediate and Long-term Efficacy of Endovascular Treatment for TASC C&D Aortoiliac Occlusive Disease

Inclusion Criteria: * Rutherford classification of 3-6 * Willing to comply with all follow-up evaluations at the specified times * Target lesion(s) located within the native infrarenal abdominal aorta and/or common iliac artery and/or external iliac artery * Evidence of ≥ 50% stenosis, restenosis (from PTA or adjunct therapy, not including stents or stent grafts), or occlusion of target lesion(s), or arterial thrombosis underwent PMT or CDT * Provides written informed consent Exclusion Criteria: * Contraindication or known untreatable allergy to antiplatelet therapy, anticoagulants, thrombolytic drugs, or any other drug used during the study * Known hypersensitivity to contrast material that cannot be adequately pretreated * Bleeding diathesis or coagulopathy, known hypercoagulable condition or refuses blood transfusion * Female currently breastfeeding, pregnant, or of childbearing potential not using adequate contraceptive measures * Life expectancy less than 24 months * Current participation in an investigational drug or other device study * Severe comorbid conditions * Myocardial infarction or stroke within 3 months prior to enrollment